Organization (Industry)
BIOVENTUS LLC
ClinicalTrials.gov lists BIOVENTUS LLC as lead sponsor of 19 trials, counting the companies grouped under it. BIOVENTUS LLC itself has 2 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BIOVENTUS LLC and 1 company grouped under it: 19 lead-sponsored trials (14 its own, 5 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Solsys Medical LLC | 5 | 0 |
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 10 |
| Osteoarthritis, Knee | 6 |
| Fractures, Bone | 2 |
| Intervertebral Disc Degeneration | 2 |
| Spondylolisthesis | 2 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 2 |
| 2021 | 2 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 3 |
| 2013 | 1 |
| 2012 | 2 |
| 2011 | 1 |
| 2008 | 2 |
| 2007 | 1 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PTP-001 | Osteoarthritis | Phase 2 | 1 |
| PTP-001 | Osteoarthritis, Knee | Phase 2 | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 80% hit target (n=5) | 1 of 4 on time (n=4) |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Trials | 2 |
| Arthritis research & therapy | 1 |
| BMJ (Clinical research ed.) | 1 |
| Clinical orthopaedics and related research | 1 |
| Macromolecular bioscience | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 130 | 24 | 2025-10-07 |
SEC-reported annual financials (8)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 568,087,000 | 22,732,000 | 12,113,000 |
| 2024 | 573,280,000 | -36,125,000 | 13,951,000 |
| 2023 | 512,345,000 | -156,230,000 | 13,446,000 |
| 2022 | 512,117,000 | -158,704,000 | 23,854,000 |
| 2021 | 430,898,000 | 19,375,000 | 19,039,000 |
| 2020 | 321,161,000 | 16,411,000 | 11,202,000 |
| 2019 | 340,141,000 | 6,851,000 | 11,055,000 |
| 2018 | not reported | not reported | not reported |
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-07-31 | Debt financing | 30,000,000 | Sec extracted |
| 2024-12-31 | Other financing | 25,000,000 | Sec extracted |
| 2024-11-04 | Other financing | not disclosed | Edgar offerings |
| 2024-09-30 | Other financing | not disclosed | Sec extracted |
| 2024-01-18 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 28 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| EXOGEN Ultrasound Coupling Gel | Class II | 2020-12-17 |
| BIOVENTUS Bioactive Bone Graft Putty 15g Rx only/sterile. Filler device intended for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. Sold under the brand names of: SIGNAFUSE, OSTEOFUSE and MEDLINE UNITE. | Class II | 2019-02-13 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2024-10-16 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Bioventus LLC | Cordova, US | FDA | |
| BIOVENTUS LLC | Durham, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (192)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-05 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-31 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-04-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 192 events.
Biomarker capability evidence (5)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| STT3A | Trial collaborator | Named in trial inclusion criteria |
| MCF2L2 | Trial sponsor | Named in trial exclusion criteria |
| CFB | Trial sponsor | Mentioned in trial text |
| MCF2L2 | Trial sponsor | Mentioned in trial text |
| STT3A | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: approved assets, fda warning letters, fda untitled letters, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.